Biblio
.
HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANT FOR RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL B-CELL LYMPHOMA. Transplant Cell Ther. 2023.
Myeloablative Fractionated Busulfan for Allogeneic Stem Cell Transplant in Older Patients or Patients with Comorbidities. Blood Adv. 2023.
Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells. Front Oncol. 2023;13:1287444.
. Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. Leuk Lymphoma. 2022:1-11.
. . Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther. 2021.
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021:JCO2002608.
Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2020:1-8.
Hematopoietic Stem Cell Transplantation for Severe Thalassemia Patients from Haploidentical Donors Using Novel Conditioning Regimen. Biol Blood Marrow Transplant. 2020.
Optimizing the Conditioning Regimen for HCT in Myelofibrosis: Long-term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant. 2020.
. .
. .
Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FLT3-ITD-positive acute myeloid leukemia cells. Biol Blood Marrow Transplant. 2014.
.